Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of... Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-COV19. Mehr anzeigen
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and...
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and...
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and...
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi; hereinafter referred to as "Meiji Seika Pharma") today announced its...
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and...
Cystic Fibrosis and OTC Deficiency Phase 2 studies on track for POC data in first half of 2025 $25 Million commercial milestone achieved with first sale of KOSTAIVE® in Japan KOSTAIVE® European...
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA vaccines and medicines company focused on the development of infectious disease vaccines...
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination PR Newswire WALTHAM, Mass. and SAN DIEGO, Sept. 30, 2024...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -2.79 | -14.8720682303 | 18.76 | 19.15 | 15.71 | 327263 | 17.35456352 | CS |
| 4 | -0.3 | -1.84388444991 | 16.27 | 20.92 | 15.5047 | 391324 | 17.57596873 | CS |
| 12 | -5.19 | -24.5274102079 | 21.16 | 25.88 | 14.9301 | 384682 | 19.23509841 | CS |
| 26 | -14.07 | -46.8375499334 | 30.04 | 30.385 | 14.9301 | 438135 | 21.13268265 | CS |
| 52 | -12.94 | -44.7595987548 | 28.91 | 45 | 14.9301 | 460136 | 27.47407661 | CS |
| 156 | -25.94 | -61.8945359103 | 41.91 | 48.75 | 11.7 | 493894 | 24.13275424 | CS |
| 260 | 5.33 | 50.0939849624 | 10.64 | 129.71 | 8.51 | 608064 | 38.0843982 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
